Sword Diagnostics at the 2010 OneMedForum
David Dingott, President and Founder of Sword Diagnostics, Inc., discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Profiles
Cleveland BioLabs at the 2010 OneMedForum
Michael Fonstein, President and CEO of Cleveland BioLabs, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Facet Solutions at the 2010 OneMedForum
Geoff Pardo, President and CEO of Facet Solutions, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum conference.
Immunomic Therapeutics at the 2010 OneMedForum
Dr. William G. Hearl, CEO of Immunomic Therapeutics, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Clarient, Inc. at the 2010 OneMedForum
Ron Andrews, CEO of Clarient, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Strategic Medicine at the 2010 OneMedForum
Michael N. Liebman, President and Managing Director of Strategic Medicine, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
TapImmune, Inc. at the 2010 OneMedForum
Denis Corin, President of TapImmune, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Jeff Eliot Margolis CFO of Xintria Pharmaceutical Corporation
Jeff Eliot Margolis, CFO of Xintria Pharmaceutical Corporation, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Echo Therapeutics Rated Strong Spec Buy by Life Tech Capital
The significant differences between Echo Therapeutics’ Symphony system and the competition is the needle-free transdermal biosensor, clinical trials in the hospital setting and biosensor life.
Access Pharma’s Drug Delivery Technology Is a Stealth Asset
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.